clinical trial · NCT06747949
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
Amgen·phase3·recruiting·n = 844
Sjögren's SyndromeDazodalibep
brief summary
The primary objective of this study is to evaluate the long-term safety and tolerability of dazodalibep.
started
Feb 25, 2025
primary completion
Dec 11, 2029
completion
Dec 11, 2029
last updated
Apr 7, 2026
official title
A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjögren's Syndrome (SS)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol